Form 4: Larimar Therapeutics CEO Carole Ben-Maimon Acquires Shares and Options

Larimar Therapeutics CEO Carole Ben-Maimon acquired 91,000 restricted stock units and 546,000 stock options on January 22, 2025.

Summary

• Carole Ben-Maimon, the President and CEO of Larimar Therapeutics, acquired 91,000 restricted stock units (RSUs) and 546,000 stock options on January 22, 2025.
• The RSUs represent a contingent right to receive one share of Larimar's common stock upon settlement.
• The stock options have an exercise price of $3.46 and expire on January 22, 2035.
• The options vest 25% on January 22, 2026, with the remaining 75% vesting monthly over the following 36 months, contingent on continued service.
• Ben-Maimon also indirectly holds 12,248 shares through the Meadow Trust, 12,249 shares through the Olivia Trust, and 12,249 shares through the Ella Trust, for which she disclaims beneficial ownership except for her pecuniary interest.

Sentiment

Score: 7

Explanation: The document reflects a positive sentiment as it shows the CEO's increased stake in the company through stock options and RSUs, indicating confidence in the company's future. However, it is a routine filing and not a major event.

Positives

• The acquisition of stock options and RSUs by the CEO demonstrates confidence in the company's future performance.
• The vesting schedule of the options incentivizes long-term commitment from the CEO.

Future Outlook

The vesting schedule of the stock options indicates a long-term commitment from the CEO to the company's success.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It provides transparency into executive compensation and ownership.

Comparison to Industry Standards

• The vesting schedule of the stock options is typical for executive compensation packages in the biotech industry, often designed to align management's interests with long-term shareholder value.
• The use of both RSUs and stock options is a common practice to provide a mix of immediate and future incentives.
• Similar filings can be seen from executives at comparable biotech companies such as BioMarin Pharmaceutical Inc. (BMRN) and Sarepta Therapeutics, Inc. (SRPT).

Stakeholder Impact

• The increased stake of the CEO may be viewed positively by shareholders, as it aligns management's interests with the company's performance.
• The vesting schedule of the options may incentivize the CEO to focus on long-term value creation.

Key Dates

Keywords

Larimar Therapeutics, Carole Ben-Maimon, stock options, restricted stock units, insider trading, executive compensation, equity, LRMR